Polymorphisms in estrogen bioactivation, detoxification and oxidative DNA base excision repair genes and prostate cancer risk

Carcinogenesis

Volumn 27, Issue 9, 2006, Pages 1842-1848

  Nock, Nora L ^a   Cicek, Mine S ^b   Li, Li ^c   Liu, Xin ^d   Rybicki, Benjamin A ^e   Moreira, Andrea ^f   Plummer, Sarah J ^f   Casey, Graham ^f   Witte, John S ^d  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b Mayo Clinic   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e HENRY FORD HEALTH SYSTEM   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYGUANINE; ARGININE; CATECHOL ESTROGEN; CATECHOL METHYLTRANSFERASE; CYSTEINE; DNA; DNA GLYCOSYLTRANSFERASE; GLUTAMINE; LEUCINE; METHIONINE; OGG1 PROTEIN; REACTIVE OXYGEN METABOLITE; SERINE; UNCLASSIFIED DRUG; VALINE;

ADULT; AGED; ARTICLE; CANCER SUSCEPTIBILITY; CAUCASIAN; CONTROLLED STUDY; DETOXIFICATION; DISEASE ACTIVITY; DNA DAMAGE; ESTROGEN ACTIVITY; EXCISION REPAIR; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR RECOGNITION; MUTATIONAL ANALYSIS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER; RISK REDUCTION;

AGED; ALLELES; CASE-CONTROL STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DNA REPAIR; ESTROGENS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; OXYGEN; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; REACTIVE OXYGEN SPECIES; RISK;

EID: 33745707363     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgl022     Document Type: Article

References (67)

1. Jemal,A., Murray,T., Ward,E., Samuels,A., Ghafoor,A., Tiwari,R.C., Feuer,E.J. and Thun,M.J. (2005) Cancer Statistics, 2005. CA. Cancer. J. Clin., 55, 10-30.
2. Bosland,M.C. (2000) The role of steroid hormones in prostate carcinogenesis. J. Natl Cancer Inst. Monogr., 27, 39-66.
3. Bostwick,D.G., Burke,H.B., Djkiew,D. et al. (2004) Human prostate cancer risk factors. Cancer, 101, 2371-2490.
4. Makridakis,N.M. and Reichardt,J.K. (2004) Molecular epidemiology of androgen-metabolic loci in prostate cancer: Predisposition and progression. J. Urol., 171, S25-S29.
5. Gsur,A., Feik,E. and Madersbacher,S. (2004) Genetic polymorphisms and prostate cancer risk. World J. Urol., 21, 2414-2423.
6. Cicek,M.S., Conti,D.V., Curran,A., Neville,P.J., Paris,P.L., Casey,G. and Witte,J.S. (2004) Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR. Prostate, 59, 69-76.
7. Cicek,M.S., Liu,X., Casey,G. and Witte,J.S. (2005) Role of androgen metabolism genes CYP1B1, PSA/KLK3, and CYP11alpha in prostate cancer risk and aggressiveness. Cancer Epidemiol. Biomarkers Prev., 14, 2173-2177.
8. Ntais,C., Polycarpou,A. and Tsatsoulis,A. (2003) Molecular epidemiology of prostate cancer: Androgens and polymorphisms in androgen-related genes. Eur. J. Endocrinol., 149, 469-477.
9. Tanaka,Y., Sasaki,M., Kaneuchi,M., Shiina,H., Igawa,M. and Dahiya,R. Polymorphisms of estrogen receptor alpha in prostate cancer. Mol. Carcinog., 37, 202-208.
10. Maggiolini,M., Recchia,A.G., Carpino,A., Vivacqua,A., Fasanella,G., Rago,V., Pezzi,V., Briand,P.A., Picard,D. and Ando,S. (2004) Oestrogen receptor beta is required for androgen-stimulated proliferation of LNCaP prostate cancer cells. J. Mol. Endocrinol., 32, 777-791.
11. Koehler,K.F., Helguero,L.A., Haldosen,L.A., Warner,M. and Gustafsson,J.A. (2005) Reflections on the discovery and significance of estrogen receptor beta. Endocr. Rev., 26, 465-478.
12. Leav,I., Galluzi,C.M., Ho,S.M. and Loda,M. (1996) Mitogen-activated protein kinase and mitogen-activated phosphatase-1 expression in Noble rat model of sex hormone-induced prostatic dysplasia and carcinoma. Lab Invest., 75, 351-370.
13. Hayes,C.L., Spink,D.C., Spink,B.C., Cao,J.Q., Walker,N.J. and Sutter,T.R. (1996) 17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc. Natl Acad. Sci. USA, 93, 9776-9781.
14. Ball,P. and Knuppen,R. (1980) Catecholoestrogens (2-and 4-hydroxyoestrogens): Chemistry, biogenesis, metabolism, occurrence and physiological significance. Acta Endocrinol. Suppl. (Copenh), 232, 1-127.
15. Yager,J.D. and Liehr,J.G. (1996) Molecular mechanisms of estrogen carcinogenesis. Ann. Rev. Pharmacol. Toxicol., 36, 203-232.
16. Cavalieri,E., Frenkel,K., Liehr,J.G., Rogan,E. and Roy,D. (2000) Estrogens as endogenous genotoxic agents - DNA adducts and mutations. J. Natl Cancer Inst. Monogr., 27, 75-93.
17. Hussain,S.P., Hofseth,L.J. and Harris,C.C. (2003) Radical causes of cancer. Nat. Rev. Cancer, 3, 276-285.
18. Muzandu,K., Shaban,Z., Ishizuka,M., Kazusaka,A. and Fujita,S. (2005) Nitric oxide enhances catechol estrogen-induced oxidative stress in LNCaP cells. Free Radic. Res., 39, 389-398.
19. Olinski,R., Zastawny,T.H., Foksinski,M., Barecki,A. and Dizdaroglu,M. (1995) DNA base modifications and antioxidant enzyme activities in human benign prostatic hyperplasia. Free Radicals Biol. Med., 18, 807-813.
20. Pathak,S.K., Sharma,R.A., Steward,W.P., Mellon,J.K., Griffiths,T.R. and Gescher,A.J. (2005) Oxidative stress and cyclooxygenase activity in prostate carcinogenesis: Targets for chemopreventive strategies. Eur. J. Cancer, 41, 61-70.
21. Martinez,G.R., Loureiro,A.P.M., Marques,S.A. et al. (2003) Oxidative and alkylating damage in DNA. Mutat. Res., 544, 115-127.
22. Greenblatt,M.S., Bennett,W.P., Holstein,M. and Harris,C.C. (1994) Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res., 54, 4855-4878.
23. Sugio,K., Ishida,T., Yokoyama,H., Inoue,T., Sugimachi,K. and Sasazuki,T. (1992) Ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. Cancer Res., 52, 2903-2906.
24. Fortini,P., Parlanti,E., Sidorkina,O.M., Laval,J. and Dogliotti,E. (1999) The type of DNA glycosylase determines the base excision repair pathway in mammalian cells. J. Biol. Chem., 274, 15230-15236.
25. Boiteux,S. and Radicella,J.P. (2000) The human OGG1 gene: Structure functions and its implication in the process of carcinogenesis. Arch. Biochem. Biophys., 377, 1-8.
26. Caldecott,K.W., McKeown,J.D., Tucker,S., Ljungquist,S. and Thompson,L.H. (1994) An interaction between the mammalian DAN repair protein XRCC1 and DNA ligase III. Mol. Cell Biol., 14, 68-76.
27. Kubota,Y., Nash,R.A., Klungland,A., Schar,P., Barnes,D.E. and Lindahl,T. (1996) Reconstitution of DNA base excision repair with purified human proteins: Interaction between DNA polymerise P and the XRCC1 protein. EMBO J., 15, 6662-6670.
28. Goodman,M.T., McDuffie,K., Hernandez,B., Wilkens,L.R., Bertram,C.C., Killeen,J., Le Marchand,L., Selhub,J., Murphy,S. and Donlon,T.A. (2001) Case-control study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism. Cancer Epidemiol. Biomarkers Prev., 10, 209-216.
29. Garner,E.I., Stokes,E.E., Berkowitz,R.S., Mok,S.C. and Cramer,D.W. (2002) Polymorphisms of the estrogen-metabolizing genes CYP17 and catechol-O-methyltransferase and risk of epithelial ovarian cancer. Cancer Res., 62, 3058-3062.
30. Mitrunen,K. and Hirvonen,A. (2003) Molecular epidemiology of sporadic breast cancer: The role of polymorphic genes involved in oestrogen biosynthesis and metabolism. Mutat. Res., 544, 9-41.
31. Sellers,T.A., Schildkraut,J.M., Pankratz,V.S. et al. (2005) Estrogen bioactivation, genetic polymorphisms, and ovarian cancer. Cancer Epidemiol. Biomarkers Prev., 14, 2536-2543.
32. Murata,M., Watanabe,M., Yamanaka,M. et al. (2001) Genetic polymorphisms in cytochrome P450 (CYP) 1A1, CYP1A2, CYP2E1, glutathione-S-transferase (GST) M1 and GSTT1 susceptibility to prostate cancer in the Japanese population. Cancer Lett., 165, 171-177.
33. Suzuki,K., Matsui,H., Nakazato,H. et al. (2003) Association of the genetic polymorphism in cytochrome P450 (CYP) 1A1 with risk of familial prostate cancer in a Japanese population: A case-control study. Cancer Lett., 195, 177-183.
34. Aktas,D., Hascicek,M., Sozen,S., Ozen,H. and Tuncbilek,E. (2004) CYP1A1 and GSTM1 polymorphic genotypes in patients with prostate cancer in a Turkish population. Cancer Genet. Cytogenet., 154, 81-85.
35. Tanaka,Y., Sasaki,M., Kaneuchi,M., Shiina,H., Igawa,M. and Dahiya,R. (2002) Polymorphisms of the CYP1B1 gene have higher risk for prostate cancer. Biochem. Biophys. Res. Commun., 296, 820-826.
36. Fukatsu,T., Hirokawa,Y., Araki,T. et al. (2004) Genetic polymorphisms of hormone-related genes and prostate cancer risk in the Japanese population. Anticancer Res., 24, 2431-2437.
37. Latil,A.G., Azzouzi,A., Cancel,G.S., Guillaume,E.C., Cochan-Priollet,B., Berthon,P.L. and Cussenot,O. (2001) Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer, 92, 1130-1137.
38. Li,L., Cicek,M.S., Casey,G. and Witte,J.S. (2004) No association between a tetranucleotide repeat polymorphism of CYP19 and prostate cancer. Cancer Epidemiol. Biomarkers Prev., 13, 2280-2281.
39. Suzuki,K., Nakazato,H., Matsui,H. et al. (2003) Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol-O-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population. Cancer, 98, 1411-1416.
40. Le Marchand,L., Donlon,T., Lum-Jones,A., Seifried,A. and Wilkens,L.R. (2002) Association of the hOGG1 Ser326Cys polymorphism with lung cancer risk. Cancer Epidemiol. Biomarkers Prev., 11, 409-412.
41. Hung,R.J., Hall,J., Brennan,P. and Boffetta,P. (2005) Genetic polymorphisms in the base excision repair pathway and cancer risk: A HuGE review. Am. J. Epidemiol., 162, 925-942.
42. Flowers,L., Bleczinski,W.F., Burczynski,M.E., Harvey,R.G. and Penning,T.M. (1996) Disposition and biological activity of benzo(a) pyrene-7,8-dione - a genotoxic metabolite generated by dihydrodiol dehydrogenase. Biochemistry, 36, 13664-13672.
43. Xu,J., Zheng,S.L., Turner,A. et al. (2002) Associations between hOGG1 sequence variants and prostate cancer susceptibility. Cancer Res., 62, 2253-2257.
44. Chen,L., Elahi,A., Pow-Sang,J., Lazarus,P. and Park,J. (2003) Association between polymorphism of human oxoguanine glycosylase 1 and risk of prostate cancer. J. Urol., 170, 2471-2474.
45. Rybicki,B.A., Conti,D.V., Moreira,A., Cicek,M., Casey,G. and Witte,J.S. (2004) DNA repair gene XRCC1 and XPD polymorphisms and risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev., 13, 23-29.
46. Van Gils,C.H., Bostick,R.M., Stern,M.C. and Taylor,J.A. (2002) Differences in base excision repair capacity may modulate the effect of dietary antioxidant intake on prostate cancer: An example of polymorphisms in the XRCC1 gene. Cancer Epidemiol. Biomarkers Prev., 11, 1279-1284.
47. Plummer,S.J., Conti,D.V., Paris,P.L., Curran,A.P., Casey,G. and Witte,J.S. (2003) CYP3A4 and CYP3A5 genotypes, haplotypes and risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev., 12, 928-932.
48. Lin,D.Y. and Wei,L.J. (1989) The robust inference for the Cox proportional hazards model. J. Am. Stat. Assoc., 84, 1074-1078.
49. Rebbeck,T.R., Jaffe,J.M., Walker,A.H., Wein,A.J. and Malkowicz,S.B. (1998) Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl Cancer Inst., 90, 1225-1229.
50. Poyurovsky,M., Michaelovsky,E., Frisch,A., Knoll,G., Amir,I., Finkel,B., Buniak,F., Hermesh,H. and Weizman,R. (2005) COMT Val158Met polymorphism in schizophrenia with obsessive-compulsive disorder: A case-control study. Neurosci. Lett., 389, 21-24.
51. Weiss,J.M., Goode,E.L., Ladiges,W.C. and Ulrich,C.M. (2005) Polymorphic variation in hOGG1 and risk of cancer: A review of the functional and epidemiologic literature. Mol. Carcinog., 42, 127-141.
52. Marsin,S., Vidal,A.E., Sossou,M., Menissier-de Murcia,J., Le Page,F., Boiteux,S., de Murcia,G. and Radicella,J.P. (2003) Role of XRCC1 in the coordination and stimulation of oxidative DNA damage repair initiated by DNA glycosylase hOGG1. J. Biol. Chem., 278, 44068-44074.
53. Wang,Y., Spitz,M.R., Zhu,Y., Dong,Q., Shete,S. and Wu,X. (2003) From genotype to phenotype: Correlating XRCC1 polymorphisms with mutagen sensitivity. DNA Repair, 2, 901-909.
54. Schwarz,D., Kisselev,P., Chernogolov,A., Schunck,W.H. and Roots,I. (2005) Human CYP1A1 variants lead to differential eicosapentaenoic acid metabolite patterns. Biochem. Biophys. Res. Commun., 336, 779-783.
55. Shimada,T., Watanabe,J., Kawajiri,K., Sutter,T.R., Guengerich,F.P., Gillam,E.M. and Inoue,K. (1999) Catalytic properties of polymorphic human cyctochrome P450 1B1 variants. Carcinogenesis, 20, 1607-1613.
56. Lachman,H., Papolos,D., Saito,T., Yu,Y.M., Szumlanski,C.L. and Weinshilboum,R.M. (1996) Human catechol-O-methyltransferase pharmacogenetics: A description of functional polymorphism and its application to neuropsychiatric disorders. Pharmacogenetics, 6, 243-250.
57. Kohno,T., Shinmura,K., Tosaka,M., Tani,M., Kim,S.R., Sugimura,H., Nohmi,T., Kasai,H. and Yokota,J. (1998) Genetic polymorphisms and alternative splicing of hOGG1 gene that is involved in repair of 8-hydroxyguanine in damaged DNA. Oncogene, 16, 3219-3225.
58. Dherin,C., Radicella,J.P., Dizdaroglu,M. and Boiteux,S. (1999) Excision of oxidatively damaged DNA bases by the human alpha-hOgg1 protein and the polymorphic alpha-hOgg1(Ser326Cys) protein which is frequently found in human populations. Nucleic Acids Res., 27, 4001-4007.
59. Yang,N., Chaudhry,M.A. and Wallace,S.S. (2005) Base excision repair by hNTH1 and hOGG1: A two edged sword in the processing of DNA damage in ac-irradiated human cells. DNA Repair, 5, 43-51.
60. Finnstrom,N., Bjelfman,C., Soderstrom,T.G., Smith,G., Egevad,L., Norlen,B.J., Wolf,C.R. and Rane,A. (2001) Detection of cytochrome P450 mRNA transcripts in prostate samples by RT-PCR. Eur. J. Clin. Invest., 10, 880-886.
61. Di Paolo,O.A., Teitel,C.H., Nowell,S., Coles,B.F. and Kadlubar,F.F. (2005) Expression of cytochromes P450 and glutathione S-transferases in human prostate and the potential for activation of heterocyclic amine carcinogens via acetyl-coA-PAPs and ATP-dependent pathways. Int. J. Cancer, 117, 8-13.
62. Ragavan,N., Hewitt,R., Cooper,L.J., Ashton,K.M., Hindley,A.C., Nicholson,C.M., Fullwood,N.J., Matanhelia,S.S. and Martin,F.L. (2004) CYP1B1 expression in prostate is higher in the peripheral than the transition zone. Cancer Lett., 215, 69-78.
63. Guldberg,H.C. and Marsden,C.A. (1975) Catechol-O-methyltransferase: pharmacological aspects and physiological role. Pharmacol. Rev., 27, 135-206.
64. Mannisto,P.T. and Kaakkola,S. (1999) Catechol-O-methyltransferase (COMT): Biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol. Rev., 51, 593-628.
65. Jiang,H., Xie,T., Ramsden,D.B. and Ho,S.L. (2003) Human catechol-O-methyltransferase down-regulation by estradiol. Neuropharmacol., 45, 1011-1018.
66. Fan,R., Kumaravel,T.S., Jalali,F., Marrano,P., Squire,J.A. and Bristow,R.G. (2004) Defective DNA strand break repair after DNA damage in prostate cancer cells: Implications for genetic instability and prostate cancer progression. Cancer Res., 64, 8526-8533.
67. DeMarzo,A.M., Utzi,M.J. and Nelson,W.G. (2001) New concepts in the pathology of prostatic epithelial carcinogenesis. Urol., 57, 103-114.